Company intelligence / Profile preview

Be+Impact

Ness Ziona, Shfella Area* / Central District†, Israelbe-impact.org ↗

Ownership: Private
Development stage: Other

Overview

ImPact Biotech's lead program, Padeliporfin VTP, has shown promising interim Phase 3 results in low-grade UTUC. In the ENLIGHTED study, 73% of response-evaluable patients achieved complete response at end of initial treatment period. The platform offers minimally invasive ablation with surgery-like efficacy without organ loss or injury risk. Additional studies are ongoing/planned for high-grade UTUC, PDAC, and NSCLC.

Therapeutic areas: Oncology
Modalities: Small molecule (Padeliporfin)Device (Laser-based photodynamic therapy)Drug-device combination therapy
Industry: Biotech

Partnerships

Collaborations with Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center.

Beyond the preview

Go deeper on Be+Impact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Be+Impact.

Explore the full profile